TMCnet News
Predictive Laboratories Launches FertilityDX™SALT LAKE CITY, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Predictive Laboratories, a wholly owned molecular and genetic diagnostics company of Predictive Technology Group (OTC Pink: PRED) focused on hard-to-detect diseases, women’s health and infertility, announces the launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments. The test launch will be formally announced at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Oct. 12-16 in Philadelphia. “For the one in eight couples who struggle with infertility, trying to have a child can be financially, physically and emotionally exhausting—largely because the couple doesn’t know why they are having difficulty conceiving,” said Kenneth Ward, M.D., Laboratory Director of Predictive Laboratories. Dr. Ward is a board-certified physician in obstetrics and gynecology, perinatology, clinical genetics and molecular genetics. “Our desire is to arm couples considering assisted reproductive technologies (ART) with an understanding of the genetic and medical obstacles that may be affecting their fertility and provide doctors with genetically relevant information to help their patients have a healthy baby.” FertilityDX provides information by evaluating three key areas: contributors to (or causes of) infertility, risks of pregnancy complications, and risks for serious genetic conditions in offspring. FertilityDX supports both physician and patient throughout the entirety of the treatment process. Patients are provided with pretest counseling and cler and relevant test results. Physicians get an easy-to-understand final report and access to a variety of genetics consultants. The test will be launched in select fertility clinics across the United States, offering couples access to the most comprehensive genetic service to date. About Predictive Laboratories The Company’s proprietary tests include ARTguideTM and FertilityDXTM. ARTguide is a blood test that assesses a woman’s endometriosis risk and other genetic causes of infertility in order to optimally navigate the path towards conception. FertilityDX is a comprehensive test and service, using the parental genetic assessment as the map to guide the journey to successful pregnancy and a healthy newborn. Predictive Laboratories’ tests are processed at the Company’s state-of-the-art CAP-accredited, CLIA-certified laboratory, equipping physicians with the robust diagnostic tools to provide personalized treatment for their patients. For more information, visit www.predictivelabs.com. About Predictive Technology Group, Inc. Forward-Looking Statements: Media Contact: Investor Contacts: |